The COVID-19 pandemic continues to change the landscape for the global pharmaceutical industry.
While there are certainly procedural and technological improvements as a result, continuing lockdowns are creating additional delays. Currently, countries pivotal to manufacturing – such as China – are still enforcing severe COVID lockdowns. Pharmaceutical companies are having to reconsider their options to take part in any person(s) in plant (PIP) activities, which remain essential even with all of the remote technology improvements. Understandably, companies are feeling the strain of such delays, but particularly biotechs – where a delay could cause a financial shutdown – are the most anxious.